Table 2.

Different cases of treated KRAS wild-type (WT) and BRAF-mutant pancreatic ductal adenocarcinoma (PDAC) in the literature

	Case I: 49-yr-old female	Case II: 65-yr-old male	Case III: 56-yr-old male	Case IV: 75-yr-old female	Case V: 60-yr-old male	Case VI: 60-yr-old female
Genomic profile	KRAS wild-type, BRAF V600E, TP53 C176R	KRAS wild-type, BRAF ΔN486_P490	KRAS wild-type, BRAF c1799_1801delTGA mutation	KRAS wild-type, BRAF V600E	KRAS wild-type, V600E	KRAS wild-type, BRAF V600E
Therapy	Dabrafenib + trametinib	Dabrafenib + trametinib	Dabrafenib + trametinib	Dabrafenib + trametinib	Vemurafenib and cobimetinib	Cobimetinib, gemzar, nab-paclitaxel
Duration of response	8 mo	4–6 mo	3 mo	19 d	6 mo	16 mo and ongoing
Dosages	Dabrafenib 300 mg twice a day with trametinib 2 mg once a day, which was later reduced by 50%; dosage of dabrafenib was later increased to 300 mg in the morning, 150 mg at night; trametinib rebegun at 2 mg two days on, one off	Dabrafenib was started at 75 mg po b.i.d. and gradually increased to full dose; trametinib was begun toward the end of treatment.	Dabrafenib 300 mg twice a day, trametinib 2 mg daily	Dabrafenib 150 mg twice daily and 2 mg trametinib once a day	Vemurafenib (960 mg twice daily) and cobimetinib (60 mg once daily, 3 wk on, 1 wk off); cobimetinib discontinued because of toxicity after 1 wk	Standard dosages of gemzar and cobimetinib 20 mg b.i.d. continuously
Side effects	Neutropenic fever and septic shock on starting dosages; tolerated reduced dose with minimal side effects	No significant side effects	Interstitial lung disease	No apparent side effects	Diffuse exanthematous rash	No apparent side effects, quality of life maintained
Line of therapy	Second-line	Fourth-line	Second-line	Second-line	Second-line	Second-line